Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Ivonescimab + Pemetrexed for Leptomeningeal Metastasis
NCT06809517Phase 2Recruiting
- Sponsor
- Guangzhou Medical University
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in leptomeningeal metastasis (LM), sponsored by Guangzhou Medical University. Started Mar 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06809517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809517.